Hansen Gwenn 4

What Happened

• Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics (NRIX), exercised stock options on Feb 3, 2026 to acquire 31,333 shares at $0.84 per share, for a cash outlay of $26,320. The same filing also shows a simultaneous disposition of 31,333 derivative shares at $0.00.
• The transactions are reported as code M (option exercise/conversion). The filing’s disposition at $0.00 may indicate shares were surrendered or withheld in connection with the exercise (common for tax withholding/cashless exercises), though the filing itself doesn’t state the specific reason.

Key Details

• Transaction date: 2026-02-03
• Acquired: 31,333 shares at $0.84 each — total $26,320
• Disposed: 31,333 derivative shares at $0.00 (reported as a disposition)
• Shares owned after transaction: not specified in this filing
• Footnote: F1 — the option exercised is fully vested
• Filing timeliness: reported on the same date (no late filing indicated)

Context

• This was an option exercise (code M). When an exercise is paired with a zero-dollar disposition, it often reflects share surrender or withholding to cover tax/option costs rather than an open-market sale; such transactions are typically administrative and not a straightforward “sell” signal.
• For retail investors: exercises are common for executives exercising vested options and don't necessarily indicate a change in sentiment.